These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 4038776)

  • 21. How efficient are rodent models for Alzheimer's disease drug discovery?
    Guo B; Zhou Q
    Expert Opin Drug Discov; 2018 Feb; 13(2):113-115. PubMed ID: 29082769
    [No Abstract]   [Full Text] [Related]  

  • 22. The older rabbit as an animal model: implications for Alzheimer's disease.
    Woodruff-Pak DS; Trojanowski JQ
    Neurobiol Aging; 1996; 17(2):283-90. PubMed ID: 8744410
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Experimental and clinical studies on the influence of desferrioxamine B on various ocular diseases. Preliminary note on corneal apoplexy].
    Campana G; Boschi MC
    Arch De Vecchi Anat Patol; 1968 Dec; 54(1):527-31. PubMed ID: 5744084
    [No Abstract]   [Full Text] [Related]  

  • 24. Deferoxamine enhances alternative activation of microglia and inhibits amyloid beta deposits in APP/PS1 mice.
    Zhang Y; He ML
    Brain Res; 2017 Dec; 1677():86-92. PubMed ID: 28963052
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drug discovery in dementia: the role of rodent models.
    Van Dam D; De Deyn PP
    Nat Rev Drug Discov; 2006 Nov; 5(11):956-70. PubMed ID: 17080031
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Alzheimer's dementia: current data review.
    Uzun S; Kozumplik O; Folnegović-Smalc V
    Coll Antropol; 2011 Dec; 35(4):1333-7. PubMed ID: 22397284
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A predictor for side effects in patients with Alzheimer's disease treated with deferoxamine mesylate.
    Kruck TP; Fisher EA; McLachlan DR
    Clin Pharmacol Ther; 1993 Jan; 53(1):30-7. PubMed ID: 8422739
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Clinical and experimental results of the treatment of some ocular diseases with desferrioxamine B].
    Campana G; Boschi MC
    Ann Ottalmol Clin Ocul; 1969 Mar; 95(3):200-24. PubMed ID: 5401431
    [No Abstract]   [Full Text] [Related]  

  • 29. Alzheimer's disease and frontotemporal dementia: prospects of a tailored therapy?
    Götz J; Ittner LM; Schonrock N
    Med J Aust; 2006 Oct; 185(7):381-4. PubMed ID: 17014407
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preventative effect of deferoxamine on degenerative changes in the optic nerve in experimental retrobulbar haematoma.
    Pelit A; Haciyakupoglu G; Zorludemir S; Mete U; Daglioglu K; Kaya M
    Clin Exp Ophthalmol; 2003 Feb; 31(1):66-72. PubMed ID: 12580898
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Aluminum and Alzheimer's disease.
    Shore D; Wyatt RJ
    J Nerv Ment Dis; 1983 Sep; 171(9):553-8. PubMed ID: 6350535
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effect of low aluminum water and desferrioxamine on the outcome of dialysis encephalopathy.
    Milne FJ; Sharf B; Bell P; Meyers AM
    Clin Nephrol; 1983 Oct; 20(4):202-7. PubMed ID: 6641027
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Alzheimer's disease in the zebrafish: where can we take it?
    Caramillo EM; Echevarria DJ
    Behav Pharmacol; 2017 Apr; 28(2 and 3-Spec Issue):179-186. PubMed ID: 28177980
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Animal models of Alzheimer's disease and evaluation of anti-dementia drugs.
    Yamada K; Nabeshima T
    Pharmacol Ther; 2000 Nov; 88(2):93-113. PubMed ID: 11150591
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical and laboratory studies on the action of desferrioxamine.
    Cumming RL; Millar JA; Smith JA; Goldberg A
    Br J Haematol; 1969 Sep; 17(3):257-63. PubMed ID: 5806435
    [No Abstract]   [Full Text] [Related]  

  • 36. Protection against tissue damage in vivo by desferrioxamine: what is its mechanism of action?
    Halliwell B
    Free Radic Biol Med; 1989; 7(6):645-51. PubMed ID: 2695408
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dementia of Alzheimer's disease and other neurodegenerative disorders--memantine, a new hope.
    Sonkusare SK; Kaul CL; Ramarao P
    Pharmacol Res; 2005 Jan; 51(1):1-17. PubMed ID: 15519530
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Studies on the use of desferrioxamine in experimental ocular siderosis produced by extrabulbar administration of iron.
    Gerkowicz K; Prost M
    Graefes Arch Clin Exp Ophthalmol; 1985; 223(2):101-5. PubMed ID: 4007505
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Canine cognitive dysfunction as a model for human age-related cognitive decline, dementia and Alzheimer's disease: clinical presentation, cognitive testing, pathology and response to 1-deprenyl therapy.
    Ruehl WW; Bruyette DS; DePaoli A; Cotman CW; Head E; Milgram NW; Cummings BJ
    Prog Brain Res; 1995; 106():217-25. PubMed ID: 8584657
    [No Abstract]   [Full Text] [Related]  

  • 40. Do raised brain aluminium levels in Alzheimer's dementia contribute to cholinergic neuronal deficits?
    King RG
    Med Hypotheses; 1984 Jul; 14(3):301-6. PubMed ID: 6472159
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.